LAVAL, Quebec—Valeant Pharmaceuticals, Inc. (NYSE/TSX: VRX) reported its total revenue for the first fiscal quarter ended March 31, 2015 was $2.2 billion, up 16 percent compared to the first quarter of 2014. Net income for Q1 was 74.5 million as compared to a loss of 20.3 million for the same period in 2014. These gains were largely driven by strong growth in many of Valeant’s U.S. businesses, including contact lenses, dermatology, neurology and oral health according to the company.

For the first quarter, Valeant posted double digit growth in the U.S. business of contact lenses, dermatology, neurology and oral health as well as double digit growth in many emerging markets including Asia, Mexico, the Middle East and Poland.

Total same organic growth was up by 15 percent for Q1, driven by the strong performance of Valeant’s business units worldwide. These include the company’s launch brands such as BioTrue Multipurpose Solution, BioTrue ONEday Contact Lens and Ultra Contact Lens in addition to pharmaceutical brands Jublia and Luzu, a company announcement said.

Consumer business for the first quarter came in at $155.5 million, up 8 percent from $144.0 million in Q1 2014. With regard to prescription ophthalmology revenues, the company reported a strong double-digit growth fueled by multiple brands with revenues generating $129.1 million for Q1. This represents a 30 percent increase as compared to $99.3 million in Q1 2014.

Overall, the contact lens market increased by 17 percent, growing from $47.7 million in Q1 2015 as compared to $40.9 million in Q1 2014. Lens care solutions have also grown by 21 percent over the past year largely driven by Biotrue Multipurpose Solution, the company said. Bausch + Lomb was acquired by Valeant in August of 2013.

“Most of the Bausch + Lomb businesses continue their consistently strong growth pattern, delivering 6 percent organic growth in Q1,” said CEO J. Michael Pearson. “If we exclude Japan, B+L grew 8 percent for the quarter. Japan enacted a sales tax increase, effective April 1, 2014, which led to a significant increase in forward buying of all consumer products in Japan, including our B+L products in Q1 of last year.”

B+L’s Ultra contact lens continues to be well-received by health care professionals and will be going into production capacity on Valeant’s private line, Pearson said.